Understand the source comparison
Peptides for Spinal Stenosis: Protocol Comparison
BPC-157 VEGF upregulation, cytokine suppression, angiogenesis 200–500 mcg daily subcutaneous Subcutaneous injection near affected region Moderate. Rodent models show consistent anti-inflammatory effects; human data limited to case reports Most investigated for
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, cytokine suppression, angiogenesis
- 200–500 mcg daily subcutaneous
- Subcutaneous injection near affected region
- Moderate. Rodent models show consistent anti-inflammatory effects; human data limited to case reports
- Most investigated for soft tissue injury; neuroprotective data emerging but not yet definitive for stenosis
- Thymosin Beta-4 (TB-4)
- Actin sequestration, anti-fibrotic activity, cellular migration support
- 2–6 mg weekly subcutaneous or intramuscular
- Subcutaneous or intramuscular injection
- Low-Moderate. Wound healing and cardiac repair studies in humans; spinal applications remain preclinical
- Theoretical benefit in preventing fibrotic nerve entrapment; lacks stenosis-specific trials
- Cerebrolysin
- Neurotrophic factor delivery (BDNF, NGF), Trk receptor activation
- 10–30 mL intravenous over 10–20 sessions
- Intravenous infusion
- Moderate-High. Human RCTs in stroke and TBI; no stenosis-specific trials
- Strongest clinical evidence base but applied to acute neuronal injury, not chronic compression
- Dihexa
- NMDA receptor modulation, synaptogenesis, cognitive enhancement
- 5–10 mg oral daily (investigational dosing)
- Oral administration
- Low. Primarily rodent cognition studies; no human safety data in neurological conditions
- Interesting mechanism for neuroplasticity but far from clinical application in stenosis
- P21
- CNTF (ciliary neurotrophic factor) mimetic, neuroprotection
- 1–5 mg subcutaneous 2–3× weekly
- Subcutaneous injection
- Very Low. Minimal published data; primarily theoretical based on CNTF pathway knowledge
- Speculative; lacks even robust preclinical validation